The GLP-1 revolution has transformed American and global medicine. Drugs like Ozempic, Mounjaro, Zepbound, and Wegovy have become household names, promising dramatic weight loss and metabolic benefits to millions.
Within the next decade, the global GLP-1 market is projected to exceed $100 billion annually. And no wonder: the sticker price for these drugs in the U.S last year ranged from $1,200 to $1,400 per month, far more than the European average cost of $350.
Yet, as demand exploded, so did something far more dangerous: a sprawling market in cheaper foreign versions and gray-market imports that patients assume are identical to what their doctor prescribed.
They are not. And the consequences can be hazardous, even life-threatening.
Boston Medical Group last year warned that purchasing Ozempic and other weight-loss drugs from unauthorized sellers is risky business, as their products can be fake or of poor quality. The FDA had already shut down more than 250 fake websites for selling counterfeit weight loss drugs or other medications.
Even worse, counterfeit medications can contain toxic substances that can result in severe reactions or unexpected health issues. If manufactured in unsanitary facilities, users can risk infections and other serious health complications, including damage to internal organs (liver and kidneys) and other difficult-to-manage conditions that may be life-threatening.
Consider what happened to Mikhail, a Russian-born American struggling with obesity who had been prescribed tirzepatide, the active ingredient in Mounjaro. Like millions of Americans, he found the price staggering.
So, when he traveled to Russia, he did what any cost-conscious patient might do: he found a locally produced version of the same drug, sold there as Sejaro, at a fraction of the U.S. price. Mikhail brought Sejaro home.
He was hospitalized after taking the imported medication for some time.
Same Drug. Different Formula. Very Different Risk.
What Mikhail didn't know was that Sejaro is not chemically identical to Mounjaro sold in the U.S. The Russian formulation contains benzyl alcohol, a preservative used to extend shelf life and reduce manufacturing costs. The FDA effectively required that benzyl alcohol be excluded from the U.S. single-dose formulation because of documented health risks.
At sufficient doses, or in vulnerable patients, benzyl alcohol can accumulate in the body and trigger metabolic acidosis -- a dangerous disruption of the body's acid-base balance that can damage organs and prove fatal. The FDA prohibits benzyl alcohol-containing medications for patients with impaired liver or kidney function, children under 12, pregnant or breastfeeding women, and those planning a pregnancy.
Mikhail developed serious kidney problems. The culprit, physicians determined, was the benzyl alcohol in his imported medication.
Mikhail is almost certainly not alone. He is just one victim whose ordeal we know about.
The Gray Market Does the Rest
Pharmaceutical manufacturers in Russia, China, India, and elsewhere around the world are moving aggressively to develop and market their own versions of these drugs targeting cost-sensitive patients.
When Mounjaro costs over $1,000 a month in the United States and a fraction of that in Russia or elsewhere, the arbitrage opportunity is obvious. Patients are ordering from Canadian online pharmacies, bringing drugs back from Mexico, and carrying medications home in their luggage. The GLP-1 gray market is not a fringe phenomenon. It is large, growing, and increasingly diverse in the products flowing through it.
What these patients are not doing is reading a foreign-language package insert. Most don't know the warning exists. Most don't know the formulation differs from what their doctor prescribed. To them, tirzepatide is tirzepatide.
Mikhail recovered. But he represents a category of patient -- cost-pressured, resourceful, and entirely unaware of formulation risk -- that numbers in the millions.
U.S. Efforts to Lower GLP-1 Prices
The original GLP-1 manufacturers are not responsible for what independent foreign producers put in their formulations. But the conditions that drove American patients into that market – high prices, inconsistent insurance coverage, no meaningful generic competition -- are a policy failure with a direct human cost.
The global race to replicate the GLP-1 miracle on the cheap has produced drugs that look identical to patients shopping on a budget. They are not identical. And until pricing, regulation, and public awareness catch up with the gray market reality, more patients like Mikhail will find that out the hard way.
The U.S has taken steps to dissuade overweight Americans from resorting to knockoff weight-loss drugs. Last November, Medicare announced it had negotiated a 71% discount on Ozempic, Wegovy, and Rybelsus, to take effect in 2027.
President Trump announced an historic reduction in U.S. prices for Ozempic and Wegovy for those who purchase the drugs through TrumpRx – to just $350.
Those reductions are good news for users but still too high for many who desperately want to lose extra pounds. The real-world floor, according to a recent research, could be as low as 75 cents to $72.49 for GLP-1A drugs. That's a price that might drive counterfeiters entirely out of the market.
